Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fremanezumab (TEV-48125) for preventive treatment of episodic migraine
jRCT2080223669Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in episodic migraine comparing Fremanezumab 225 mg monthly, Fremanezumab 675 mg loading dose then placebo and Placebo (3 arms). Primary endpoint: Efficacy over 3 months of fremanezumab for episodic migraine prevention. Started Oct 2017; status: completed.
02
Drugs
fremanezumab
03
Conditions
episodic migraine
Beyond the preview
Go deeper on jRCT2080223669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223669.